250 related articles for article (PubMed ID: 18374336)
1. Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study.
Leonhardt W; Pfützner A; Müller J; Pietzsch J; Forst T; Karagiannis E; Lübben G; Hanefeld M
Atherosclerosis; 2008 Nov; 201(1):155-62. PubMed ID: 18374336
[TBL] [Abstract][Full Text] [Related]
2. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
[TBL] [Abstract][Full Text] [Related]
3. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease.
Kontopoulos AG; Athyros VG; Papageorgiou AA; Hatzikonstandinou HA; Mayroudi MC; Boudoulas H
Coron Artery Dis; 1996 Nov; 7(11):843-50. PubMed ID: 8993943
[TBL] [Abstract][Full Text] [Related]
4. The role of pioglitazone in modifying the atherogenic lipoprotein profile.
Hanefeld M
Diabetes Obes Metab; 2009 Aug; 11(8):742-56. PubMed ID: 19519869
[TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study.
Hanefeld M; Marx N; Pfützner A; Baurecht W; Lübben G; Karagiannis E; Stier U; Forst T
J Am Coll Cardiol; 2007 Jan; 49(3):290-7. PubMed ID: 17239709
[TBL] [Abstract][Full Text] [Related]
6. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
7. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins.
Geiss HC; Otto C; Parhofer KG
Metabolism; 2006 May; 55(5):599-604. PubMed ID: 16631435
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous properties of intermediate- and low-density lipoprotein subpopulations.
Srisawasdi P; Vanavanan S; Rochanawutanon M; Pornsuriyasak P; Tantrakul V; Kruthkul K; Kotani K
Clin Biochem; 2013 Oct; 46(15):1509-15. PubMed ID: 23830843
[TBL] [Abstract][Full Text] [Related]
9. Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.
Lewin AJ; Kipnes MS; Meneghini LF; Plotkin DJ; Perevozskaya IT; Shah S; Maccubbin DL; Mitchel YB; Tobert JA;
Clin Ther; 2004 Mar; 26(3):379-89. PubMed ID: 15110130
[TBL] [Abstract][Full Text] [Related]
10. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
McCormack T; Harvey P; Gaunt R; Allgar V; Chipperfield R; Robinson P;
Int J Clin Pract; 2010 Jul; 64(8):1052-61. PubMed ID: 20487050
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study.
Winkler K; Konrad T; Füllert S; Friedrich I; Destani R; Baumstark MW; Krebs K; Wieland H; März W
Diabetes Care; 2003 Sep; 26(9):2588-94. PubMed ID: 12941723
[TBL] [Abstract][Full Text] [Related]
12. Differences in the results and interpretation of oxidized LDL cholesterol by two ELISA assays--an evaluation with samples from the PIOstat study.
Pfützner A; Efstrathios K; Löbig M; Armbruster FP; Hanefeld M; Forst T
Clin Lab; 2009; 55(7-8):275-81. PubMed ID: 19894406
[TBL] [Abstract][Full Text] [Related]
13. Differences in the low density lipoprotein subfraction profile between oral contraceptive users and controls.
de Graaf J; Swinkels DW; Demacker PN; de Haan AF; Stalenhoef AF
J Clin Endocrinol Metab; 1993 Jan; 76(1):197-202. PubMed ID: 8421088
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease.
Abel T; Fehér J; Dinya E; Eldin MG; Kovács A
Med Sci Monit; 2009 Dec; 15(12):MS6-11. PubMed ID: 19946244
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).
Nicholls SJ; Brandrup-Wognsen G; Palmer M; Barter PJ
Am J Cardiol; 2010 Jan; 105(1):69-76. PubMed ID: 20102893
[TBL] [Abstract][Full Text] [Related]
16. The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients.
Hajer GR; Dallinga-Thie GM; van Vark-van der Zee LC; Visseren FL
Atherosclerosis; 2009 Jan; 202(1):216-24. PubMed ID: 18533158
[TBL] [Abstract][Full Text] [Related]
17. The effect of simvastatin treatment on the low-density lipoprotein subfraction profile and composition in familial hypercholesterolaemia.
de Graaf J; Demacker PN; Stalenhoef AF
Neth J Med; 1993 Dec; 43(5-6):254-61. PubMed ID: 8107933
[TBL] [Abstract][Full Text] [Related]
18. Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease.
Le NA; Tomassini JE; Tershakovec AM; Neff DR; Wilson PW
J Am Heart Assoc; 2015 Oct; 4(10):e001675. PubMed ID: 26486166
[TBL] [Abstract][Full Text] [Related]
19. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM
Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274
[TBL] [Abstract][Full Text] [Related]
20. Effects of increasing doses of simvastatin on fasting lipoprotein subfractions, and the effect of high-dose simvastatin on postprandial chylomicron remnant clearance in normotriglyceridemic patients with premature coronary sclerosis.
van Wijk JP; Buirma R; van Tol A; Halkes CJ; De Jaegere PP; Plokker HW; van der Helm YJ; Castro Cabezas M
Atherosclerosis; 2005 Jan; 178(1):147-55. PubMed ID: 15585212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
